Guideline-driven intervention on SCI-associated dyslipidemia, metabolic syndrome, and glucose intolerance using pharmacological agents

Research output: Contribution to journalReview article

5 Scopus citations

Abstract

This review summarizes current thinking and evidence-based recommendations for pharmacotherapy in the treatment of dyslipidemia, metabolic syndrome, and glucose intolerance as a basis for their application to individuals with a spinal cord injury (SCI). Although the evidence that subjects with an SCI are categorically at increased risk for cardiovascular disease is mixed, a significant number of such patients have cardiometabolic risk factors and therefore a systematic approach to this problem is important. The guidelines discussed are those recommended by the Adult Treatment Panel III of the National Cholesterol Education Program. These focus primarily on low-density lipoprotein LDL cholesterol (LDL-C). Several cardiometabolic risk factors such as hypertriglyceridemia, low high-density lipoprotein cholesterol (HDL-C), and glucose intolerance constitute possible targets for pharmacotherapy beyond LDL-C.

Original languageEnglish (US)
Pages (from-to)46-57
Number of pages12
JournalTopics in Spinal Cord Injury Rehabilitation
Volume14
Issue number3
DOIs
StatePublished - Dec 1 2009

Keywords

  • Dyslipidemia
  • Glucose intolerance
  • Metabolic syndrome
  • Pharmacotherapy

ASJC Scopus subject areas

  • Clinical Neurology
  • Rehabilitation
  • Physical Therapy, Sports Therapy and Rehabilitation

Fingerprint Dive into the research topics of 'Guideline-driven intervention on SCI-associated dyslipidemia, metabolic syndrome, and glucose intolerance using pharmacological agents'. Together they form a unique fingerprint.

  • Cite this